None listed
Conditions
Interventions
Drug : 1. Investigational Product(EG-Myocin)
2. Placebo(EG-Myocin ??)
Sponsors
Eyegene
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Ability to provide informed consent - Male : 19 ~ 75 years, Female : 50 ~ 75 years - ST-segment elevation myocardial infarction - PPCI - Able to consent for blood draw
Exclusion criteria
Exclusion criteria: - Left main coronary artery - Cardiac arrest or arrhythmia where CPR or unscheduled circulatory aids have been used during diagnosis - Cardiac shock - uncontrolled hypertension - CABG, coronary artery bypass graft - An arrhythmia patient who has clinically significant - Severe renal disorders - Severe liver disorders - Medical history of malignant carcinoma within past 3 years - Subjects who have hypersensitivity reaction anamnesis for components of Investigational Product. - Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or previous enrolment in this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inhibitory Effect of Investigational Medicinal Product on Myocardial Ischemia / Reperfusion Injury | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect of Investigational Medicinal Product on Physiological Status of Myocardial Infarction | — |
Countries
Korea, Republic of
Contacts
Public ContactChul-Min Ahn
Yonsei University Health System, Severance Hospital
Outcome results
None listed